Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

INDIANAPOLIS, Nov. 28 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain. Lilly plans to resubmit the application in the first half of 2009, adding data from a recently completed positive study in chronic osteoarthritis pain of the knee.

The decision does not affect duloxetine's FDA-approved indications for major depressive disorder, generalized anxiety disorder, management of diabetic peripheral neuropathic pain and management of fibromyalgia.

Lilly submitted the chronic pain application in the second quarter of 2008 based primarily on outcomes of three clinical trials: one positive study in chronic osteoarthritis pain of the knee(i) and two studies(ii,iii), -- one positive and one that is supportive but didn't meet its primary endpoint -- in chronic low back pain. In discussions between Lilly and the FDA, agency reviewers raised questions about efficacy and dosing that revolved primarily around statistical methodology and study design.

"This was a difficult decision, but we believe the updated data package will give the FDA a broader basis for reviewing our application," said John Hayes, M.D., a Lilly Research Laboratories vice president at Lilly.

Chronic pain affects more than 50 million Americans(iv) and pain is a major cause of work absenteeism, underemployment and unemployment.(v,vi,vii,viii)

About Duloxetine

Serotonin and norepinephrine in the brain and spinal cord are believed to both mediate core mood symptoms and help regulate the perception of pain. Based on preclinical studies, Duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is bel
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 This report analyzes the worldwide markets ... the following Segments: Standard Intraocular Lenses, and Premium Intraocular Lenses. ... Canada , Japan , ... Latin America , and Rest of World. Annual ... 2020. Also, a seven-year historic analysis is provided for these ...
(Date:5/28/2015)... , May 28, 2015 Isis Pharmaceuticals, ... , Akcea Therapeutics WebcastWhen: , Thursday, June 4 at ... www.isispharm.com How: , Live on the Internet.  Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
(Date:5/28/2015)... 2015   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... at the Jefferies 2015 Healthcare Conference on Wednesday, June ... New York .  Lexicon management will provide ... A webcast of the presentation will be ... archived version of the presentation will be available at ...
Breaking Medicine Technology:World Intraocular Lenses Industry 2World Intraocular Lenses Industry 3World Intraocular Lenses Industry 4World Intraocular Lenses Industry 5World Intraocular Lenses Industry 6World Intraocular Lenses Industry 7World Intraocular Lenses Industry 8World Intraocular Lenses Industry 9World Intraocular Lenses Industry 10World Intraocular Lenses Industry 11World Intraocular Lenses Industry 12World Intraocular Lenses Industry 13World Intraocular Lenses Industry 14World Intraocular Lenses Industry 15World Intraocular Lenses Industry 16World Intraocular Lenses Industry 17World Intraocular Lenses Industry 18World Intraocular Lenses Industry 19World Intraocular Lenses Industry 20World Intraocular Lenses Industry 21World Intraocular Lenses Industry 22World Intraocular Lenses Industry 23World Intraocular Lenses Industry 24World Intraocular Lenses Industry 25World Intraocular Lenses Industry 26Webcast Alert: Akcea Therapeutics Conference Call 2Webcast Alert: Akcea Therapeutics Conference Call 3Lexicon To Present At The Jefferies 2015 Healthcare Conference 2
... BARCELONA, Spain , June 1 Clinicians at Institut Catala ... in Spain using RapidArc® radiotherapy from Varian Medical Systems (NYSE: ... the first patient in the country to receive the fast and efficient ... "The treatment went ...
... BEIJING , June 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: ... it has received,the confirmation from the China International Tendering Company that Sinovac,was ... supply the Company,s hepatitis A vaccine, Healive, to the,Beijing Expanded Program of ... ...
Cached Medicine Technology:Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 2Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 3Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 4Sinovac Selected by Beijing CDC to Supply Hepatitis A Vaccine Healive(R) 2Sinovac Selected by Beijing CDC to Supply Hepatitis A Vaccine Healive(R) 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Mediaplanet has ... “beauty of protection”. Skin Health is a cross-platform ... within the markets of New York, Los Angeles, and ... 750,000 readers. Its digital counterpart will reach a national ... To read more the Skin Health campaign and Colorescience, ...
(Date:5/29/2015)... Dallas, TX (PRWEB) May 29, 2015 ... H1 2015” provides comprehensive information on the therapeutic ... different types of muscles in the body, leading ... strengthens R&D pipelines by identifying new targets and ... report on H1 2015 pipeline review of Axillary ...
(Date:5/29/2015)... Designed with the versatile athlete in mind, BPI ... new, exclusive line of supplementation called The 24/7 Series. ... greatest, high impact, result driven ingredients that have been ... Series can be used by anyone from bodybuilders to ... enthusiasts. There are no stimulant based ingredients that cause ...
(Date:5/29/2015)... The annual aesthetic meeting, put on by ... in Montreal from May 14-19th. This global event sets ... around the world; dedicating itself exclusively to cosmetic medicine. ... plastic surgeons to attend this year’s meeting. , Among ... Vitenas was given the honor of sitting at the presenter’s ...
(Date:5/29/2015)... Dallas, TX (PRWEB) May 29, 2015 ... Pipeline Review, H1 2015” provides comprehensive information ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report on H1 ... 18 market data tables and 13 figures, ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3
... Today AXA Equitable,unveiled its new Athena Survivorship ... to deliver cost-effective death benefit,protection to couples and ... needs. By providing a death benefit upon the ... be used to pay sizeable estate,taxes and other ...
... ... Care, STANFORD, ... have donated $150,000 to Lucile,Packard Children,s Hospital at Stanford to expand clinical ... PI is a term that encompasses more than 150 diseases caused ...
... Boston, MAScientists at Schepens Eye Research Institute have ... of tear production are more likely to develop ... situ keratomileusis), laser refractive surgery to correct near- ... Their research, published in the January issue of ...
... ... Processes, NEW ORLEANS, March 3 ... serving science, today launched,significant new technologies at PITTCON 2008 that are designed ... and,applications. PITTCON, the world,s largest conference and exposition for,laboratory science, is under ...
... the FORTUNE ... Survey, MILWAUKEE, March 3 ... 2008 annual survey, FORTUNE,magazine ranked the company as "America,s Most Admired" in the ... have led its industry every year it has been included in,the prestigious survey ...
... , In humans, as in all mammals, ... alternates with dream phases, called Rapid Eye Movement (REM)-sleep. ... memories are consolidated during sleep, this remains a hotly ... help to clarify the function of sleep by revealing ...
Cached Medicine News:Health News:AXA Equitable Meets the Needs of Two People under One Life Insurance Policy 2Health News:AXA Equitable Meets the Needs of Two People under One Life Insurance Policy 3Health News:Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford 2Health News:Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford 3Health News:Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford 4Health News:Scientists discover who is likely to get dry eye syndrome after LASIK surgery 2Health News:Thermo Fisher Scientific Showcases Product Innovation at PITTCON 2008 2Health News:Thermo Fisher Scientific Showcases Product Innovation at PITTCON 2008 3Health News:Thermo Fisher Scientific Showcases Product Innovation at PITTCON 2008 4Health News:Thermo Fisher Scientific Showcases Product Innovation at PITTCON 2008 5Health News:Thermo Fisher Scientific Showcases Product Innovation at PITTCON 2008 6Health News:Northwestern Mutual Is 'America's Most Admired' for an Unprecedented 25th Year 2Health News:'Power napping' in pigeons 2
Qualitative EIA for SS-A, SS-B, Sm, Sm/RNP plus Scl-70 and Jo-1...
... Automation, Inc. (DAI) ENA Profile Enzyme-Linked Immunosorbent ... of antibodies in human serum to individually ... Scl-70 and Jo-1 in a single serum ... to be used as an aid in ...
... This is an enzyme immunoassay(EIA) ... antibodies to extractable nuclear antigens Sm, ... in human serum. The results from ... an aid in the diagnosis of ...
... Screening Kit is designed to screen patient samples ... microtiter well is coated with Sm, RNP, SS-A, ... laboratory to cost effectively screen out the ENA ... specificity on any of the company's other RELISA ...
Medicine Products: